product catalogue

Diagnostics

PRODUCT CATALOG

www.bioporto.com www.antibodyshop.com www.ngal.com

Welcome to our product catalogue 2010

Thank you for taking the time to review this catalogue of ELISA kits and antibodies. 2009 has been a busy and exciting year here at BioPorto Diagnostics - we added new and innovative products to all areas of our portfolio and we hope you fi nd inspiration in our offering. An area that naturally got special attention is NGAL - our patented biomarker for the early diagnosis of acute kidney injury. We successfully developed The NGAL Test, based on the principle of turbidimetry can be used on a wide range of automated clinical chemistry analyzers. These types of open instruments are already running in laboratories and hospitals all over the world, making this sought after test readily accessible without sizeable investments in expensive new machines. The NGAL Test will be available in the beginning of 2011 and pre-orders are very welcome. The pharma NGAL portfolio is a focus point as well – we now offer monoclonal antibodies against NGAL in dog or pig and new ELISA kits for NGAL testing in dog and mouse have been added to the portfolio. We expect to launch ELISA kits for pig and monkey NGAL during 2010. The launch of the unique APC-PCI ELISA kit was an important milestone. Studies indicate that this groundbreaking marker may play a role in selecting sepsis patients for human recombinant APC (Xigris®, Eli Lilly) treatment. Also, do not miss out on our focused range of obesity and type-2 diabetes antibodies. It is our endeavour to continue introducing high-quality products that complement the work you do. We strongly believe that product development comes from the customer, not the company, so your feedback and suggestions will be invaluable.

Yours sincerely,

Thea Olesen Chief Executive Offi cerBioPorto Diagnostics A/S

BioPorto® Diagnostics Human NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Animal NGAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 APC-PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Mannan-binding lectin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

AntibodyShop®

Monoclonal antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Cell biology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Coagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Collectins and related products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Complement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Cytokines and hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Marker molecules. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Miscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Other blood proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Sera and antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Abbreviations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Alphabetical product index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

Ordering information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Distributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Diagnostics

ABOUT USBioPorto Diagnostics A/S is a Danish company which develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefi t of individual patients and to promote effi ciency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney injury.

BioPorto was founded in 2000 and is listed on the NASDAQ OMX Copenhagen (symbol: BIOPOR).

BioPorto Diagnostics’ strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.

QUALITY POLICYBioPorto Diagnostics is committed to the highest level of quality in the manufacture, sale and support of its products. Quality and compliance with all applicable regulatory requirements and customer satisfaction must underlie the company’s efforts in manufacturing, marketing, sales, shipping and technical support.

BioPorto Diagnostics is committed to effectively implementing and continuously improving its quality management system in accordance with the European IVD directive, the Canadian medical device regulations and ISO 13485 requirements, and is currently seeking certifi cation to this standard.

BioPorto Diagnostics aims to please the customers while paying due regard to the interests of the company’s stakeholders.

NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased after kidney injury, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.

Clinical signifi cance

NGAL levels may also be moderately raised in infections and certain cancers. Rises in NGAL above the baseline level for the patient may indicate acute kidney injury which may lead to acute renal failure. NGAL determination is relevant in, amongst others:

Critically ill patients1, 2

Kidney transplants3, 4

Use of i.v. X-ray contrast agents5, 6

30% or more of patients in intensive care may suffer some degree of acute renal failure. The onset of acute renal failure on top of other critical illness increases the mortality dramatically. The prognosis of acute renal failure has not improved signifi cantly over the last four decades. Current diagnostic methods such as serum creatinine or cystatin C measurements only respond after renal function has deteriorated, which may or may not become apparent until one or more days after the original insult. With the NGAL Rapid ELISA Kit, physicians can initiate appropri-ate management of acute kidney injury within hours rather than days after the insult.

Studies by BioPorto Diagnostics1 have shown that the mean NGAL concentration in urine from healthy donors was 5.3 ng/mL (range 0.7-9.6 ng/mL). The mean NGAL concentration in plasma from healthy donors was 63 ng/mL (range 37-106 ng/mL). NGAL levels rise steeply immediately after kidney injury. In unselected patients admitted to intensive care, the NGAL concentrations in urine ranged from 110 ng/mL to 40,000 ng/mL, while the mean NGAL concentra-tion in EDTA plasma ranged from 25 ng/mL to 3500 ng/mL. Urinary levels above a cut-off of 350 ng/mL or plasma levels above 400 ng/mL are associated with acute renal failure, with a positive predictive value of approximately 90%.

Urinary NGAL after a moderate renal insult

Illustrative time-course of the urinary NGAL level after a moderate renal insult.

The red line represents a patient that with 90% positive predictive value will develop acute renal failure, while the green line represents a patient that will not develop acute renal failure.

Prognostic cut-off

Actin releasing event Survivor

Non-survivor

Diagnostic cut-off

Diagnostics

Human NGAL

NGAL ELISA KitNGAL Rapid ELISA Kit† IVD * In development: The NGAL Test - For your clinical chemistry analyzer

With the NGAL ELISA Kit (KIT 036) and the NGAL Rapid ELISA Kit (KIT 037), urine, plasma or serum samples can be analyzed with conventional ELISA equipment. Automation is also possible on open ELISA workstations.All kit components are ready to use and conveniently stored at 4°C. D

iagnostics

References 1. Bangert K, Heslet L, Ghiglione M, Uttenthal LO (2006) NGAL is signifi cantly increased in urine and plasma in acute renal failure.

Intensive Care Med 32 (Supplement 1):S10.

2. Makris K, Markou N, Evodia E, Dimopoulou E, Drakopoulos I, Ntetsika K, Rizos D, Baltopoulos G, Haliassos A (2009) Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 47:79-82.

3. Kusaka M, Kuroyanagi Y, Mori T, Nagaoka K, Sasaki H, Maruyama T, Hayakawa K, Shiroki R, Kurahashi H, Hoshinaga K (2008) Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant 17:129-134.

4. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M (2009) Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 41:158-161.

5. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006) Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26:287-292.

6. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A, Calandra S, Noto P, Le Moli C, Alongi B, Nigro F (2009) Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci 13:197-200.

Cat. No. Product name Size

KIT 037 NGAL Rapid ELISA Kit 96 wells

WASH 037-30 25x Wash Solution Concentrate for KIT 037 30 mL

KIT 036 NGAL ELISA Kit 96 wells

* Please visit www.bioporto.com for availability in your country.† BioPorto’s NGAL cutoff patent WO2006066587 covering the measurement of NGAL as a marker for acute kidney injury is issued in

South Africa, New Zealand and Singapore and is approved for issue in Europe.

KIT 036 4-hour assay format For Research Use Only. Not for use in diagnostic

procedures Dynamic range is 100 fold (10 – 1000 pg/mL)

KIT 037 1-hour rapid assay format For in-vitro diagnostic (IVD) use in selected

countries* Dynamic range is 100 fold (0.2 – 20 ng/mL)

NGAL ELISA Kits

Diagnostics

Animal NGAL

NGAL, also called lipocalin 21,2, is the new rapidly responding biomarker of kidney injury whose wide applications include:

Drug development (toxicology, dose calculation, drug safety and effi cacy assessment) Diagnostic use (kidney injury of any cause) Basic research

NGAL – the biomarker in renal toxicology

Early establishment of drug safety is a continuing challenge in drug development. Exploiting the advantages of new biomarkers related to specifi c organ damage is attracting the attention of the pharmaceutical industry and regulatory bodies. Clinical studies and experimental animal models have shown that NGAL could be of great value as a marker of kidney damage in both human diagnostics and drug development. Because of its rapid, sensitive and graded response in kidney injury, NGAL permits the early assessment of the renal toxicity or safety of new compounds or treatments.

Important applications of NGAL measurements are:

Safety biomarker - NGAL levels rise when the kidney is damaged Effi cacy biomarker - NGAL levels fall when kidney damage is treated

Diagnostic use and basic researchNGAL undergoes an early and dramatic up-regulation in various nephron segments after kidney injury, whether this be ischemic3,4, nephrotoxic4,5 or infectious6 in origin. Rises of NGAL concentrations in urine, plasma or serum can be used in research and preclinical studies to detect the extent of kidney injury. The use of NGAL determination will also extend to veterinary diagnostics in farm animals and pets.

Discovery Pre-clinical R&D Clinical P1 Clinical P3Clinical P2 Clinical P4

Animal NGAL

Animal NGAL ELISA Kits

Monoclonal antibodies to animal and human NGAL

Key features Highly reproducible results Easy to use Easy storage at 4°C

BioPorto Diagnostics’ animal NGAL ELISA kits are based on sandwich ELISA using specifi c, high-affi nity monoclonal anti-bodies, and the total test time is less than 4 hours.

References 1. Kjeldsen L, Cowland JB, Borregaard N (2000) Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat

and mouse. Biochim Biophys Acta 1482:272-83. 2. Flower DR (1996) The lipocalin protein family: structure and function. Biochem J 318:1-14. 3. Matthaeus T, Schulze-Lohoff E, Ichimura T, Weber M, Andreucci M, Park KM, Alessandrini A, Bonventre JV (2001) Co-upregulation

of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic kidney. J Am Soc Nephrol 12:787A.

4. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identifi cation of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534-2543.

5. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24:307-315.

6. Ichino M, Kuroyanagi Y, Kusaka M, Mori T, Ishikawa K, Shiroki R, Kurahashi H, Hoshinaga KJ (2009) Increased urinary neutrophil gelatinase associated lipocalin levels in a rat model of upper urinary tract infection. Urol 181:2326-31.

Diagnostics

Nephrotoxicity studyNGAL concentrations in rat serum and urine from control rats and rats given 10 mg/kg cisplatin intraperitoneally.

Dilution factor

100 1000 10000 100000 1000000

10 Serum Urine0 200 400 800 1600 3200 6400 12800 25600 51200

Control Cisplatin

To supplement our animal and human NGAL ELISA kits, we also offer a range of monoclonal antibodies to NGAL from the animal species that are most used by researchers and the pharmaceutical industry:

mouse | rat | guinea pig | dog | cat | pig | monkey | human

This makes NGAL the fi rst kidney injury or toxicology biomarker to cover all the standard animal models of basic research and drug discovery. The antibodies can be used individually or in sandwich pairs and thus have a wide range of applications in immunoassays.

KIT 041 Rat NGAL ELISA Kit 96 wells

KIT 042 Mouse NGAL ELISA Kit 96 wells

KIT 043* Dog NGAL ELISA Kit 96 wells

KIT 044* Pig NGAL ELISA Kit 96 wells

KIT 045* Monkey NGAL ELISA Kit 96 wells

*Coming soon.

Animal NGAL ELISA Kits

Activated protein C-protein C inhibitor (APC-PCI) complex starts being formed as soon as protein C (PC) is activated on the blood vessel wall and the active enzyme (APC) enters into contact with its specific circulating serpin, protein C inhibitor (PCI). The resulting inactive APC-PCI complex is thus a marker of PC activation.

APC-PCI – a potential marker for evaluating sepsis patients for APC treatment

Sepsis is a devastating condition characterized by systemic activation of the inflammatory and coagulation cascades in response to microbial infection. Apart from antimicrobial therapy, the infusion of human recom-binant APC (Xigris®, Eli Lilly) is the only treatment documented to reduce the mortality of sepsis patients. The effect of Xigris® has been modest1 so far, largely due to the fact that selecting the right patients for this treatment has been a challenge. Now, a study of APC-PCI levels in sepsis patients conducted by BioPorto Diagnostics suggests that measuring APC-PCI levels predicts outcome and may have a role in selecting patients for treatment2.

In the preliminary study both low (APC-PCI levels within the normal range) and high protein C activation indicated a high mortality in sepsis, whereas a moderate activation (APC-PCI elevated to no more than about 3-fold higher than the upper limit of normal) is associated with a reduced mortality. These data clearly point to the use of APC-PCI for risk stratification of sepsis patients, and also to a possible solution to the problem of how best to select sepsis patients for specific treatments such as Xigris® 3.

The relationship between mortality and protein C activation differs in critically ill patients with and without sepsis. In sepsis patients, both failure of protein C activation and high protein C activation are associated with high mortality. Sepsis patients without protein C activation and an APACHE II score <25 have a particularly high mortality and may be those who are most likely to benefit from APC treatment2.

APC-PCI in coagulation

APC splits blood coagulation factors Va and VIIIa, using protein S and blood coagulation factor V as cofactors. It thereby limits blood coagulation in the vicinity of membrane-bound factors Va and VIIIa. APC may also have an indirect fibrinolytic activity by inhibiting plasminogen activator inhibitor-1 and by limiting the generation of activated thrombin-activatable fibrinolysis inhibitor. APC-PCI levels are elevated in several thrombotic condi-tions, and measuring APC-PCI levels may be relevant in several conditions such as deep vein thrombosis, myocardial infarctions and aortic aneurysms4-6.

APC-PCI

Diagnostics

None Moderate

Activation of protein C

None Moderate High

Sepsis Non-sepsis

APACHE II<25 APACHE II>25

None Moderate

Activation of protein C

None Moderate High

Sepsis Non-sepsis

APACHE II<25 APACHE II>25

APC-PCI

APC-PCI ELISA Kit

References 1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW,

Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709.

2. Heslet L, Hald R, Recke C, Bangert K, Uttenthal LO (2008) Activated protein C-protein C inhibitor (APC-PCI) complex as a prognostic marker in sepsis. Presented at the The International Sepsis Forum (ISF) 2008, Granada, Spain.

3. Patent application number PCT/DK2007/050194

4. Strandberg K, Astermark J, Björgell O, Becker C, Nilsson PE, Stenflo J (2001) Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 86:1400-1408.

5. Bhiladvala P, Strandberg K, Stenflo J, Holm J (2006) Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex. Thromb Res 118:213-219.

6. Kölbel T, Strandberg K, Mattiasson I, Stenflo J, Lindblad B (2006) Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg 43:935-939.

BioPorto Diagnostics’ APC-PCI ELISA Kit measures activated protein C–protein C inhibitor complex in human plasma. For Research Use Only. Not for use in diagnostic procedures.

Key features The only commercially available APC-PCI ELISA Kit Uses exclusive patented antibodies Precoated Microwell strips can be used as strips of 8 or as individual wells All components are stored at 2-8˚C

Diagnostics

KIT 040 APC-PCI ELISA Kit 96 wells

APC-PCI ELISA Kit

Mannan-binding lectin (MBL)

Clinical signifi cance

Defi ciency of MBL has been shown to increase the overall susceptibility to infectious diseases and to predispose to greater disease severity; hence especially early and aggressive treatment with antibiotics can be required in risk patients such as those on cancer chemotherapy or immunosuppressant treatment.

MBL is a key test parameter in:

Patients with a suspected primary immunodefi ciency Children with recurrent infections3, 4

Adults with recurrent, severe & persistent infections5, 6

Immunosuppressed patients Cancer chemotherapy7, 8

Transplantation9

Patients with cystic fi brosis10, 11

Patients with autoimmune diseases Systemic lupus erythematosus12

Rheumatoid arthritis13

Women with recurrent spontaneous abortions14, 15

MBL in complement activation

The complement system is a set of blood proteins that form a proteolytic enzyme cascade to help clear pathogens from the body. MBL binds specifi cally to microbial surface carbohydrates and activates the complement system by means of the MASP-dependent lectin pathway, the MASPs being proteolytic enzyme precursors bound to MBL. This leads to the phagocytosis or lysis of pathogenic microorganisms, including bacteria, viruses, protozoa and fungi.

Only the normally oligomerized forms of MBL are functional, i.e. capable of binding effi ciently to microbial carbohydrates and associating with the MASPs.

– a key test in the assessment of primary immunodeficiency

Mannan-binding lectin (MBL) is an important component of the innate immune system. However, in at least 12% of the average Caucasian population, the circulating level of functional MBL is insuffi cient. This makes MBL defi ciency by far the most common primary immunodefi ciency1. While the consequences of MBL defi ciency can be quite subtle, several studies have shown that MBL defi ciency increases susceptibility to infectious diseases and predisposes to greater severity when infections occur. This correlation has not only led to an increase in the routine diagnostic use of MBL measurement, but has also pointed to a need for therapeutic applications of MBL2.

Mannan-binding lectin

Diagnostics

MBL Oligomer ELISA Kit *

The MBL Oligomer ELISA Kit employs a monoclonal antibody sandwich which is highly specific for normally oligomer-ized MBL molecules. Hence the results obtained with the KIT 029 correspond to the circulating levels of “functional” MBL.

Key features Measures oligomerized

“functional” MBL Measures in plasma and serum All reagents are ready-to-use Storage at 2-8°C For in-vitro diagnostic (IVD) use in

selected countries* Can be used in many different

automated ELISA workstations

References 1. Turner MW (2003) The role of mannose-binding lectin in health and disease. Mol Immunol 40:423-429. 2. Summerfield JA (2003) Clinical potential of mannose-binding lectin-replacement therapy. Biochem Soc Trans 31:770-773. 3. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, Hansen CH, Andersen LH, Hahn GW, Garred P (2001) Acute

respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 285:1316-1321. 4. Forster-Waldl E, Cokoja L, Foster D, Maurer W (2003) Mannose-binding lectin: comparison of two assays for the quantification of

MBL in the serum of pediatric patients. J Immunol Methods 276:143-146. 5. Eisen DP, Dean MM, Boermeester MA, Fidler KJ, Gordon AC, Kronborg G, Kun JF, Lau YL, Payeras A, Valdimarsson H, Brett SJ,

Ip WK, Mila J, Peters MJ, Saevarsdottir S, van Till JW, Hinds CJ, McBryde ES (2008) Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 47:510-516.

6. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, Aspa J, Briones ML, Garcia-Saavedra A, Rajas O, Blanquer J, Caballero-Hidalgo A, Marcos-Ramos JA, Hernandez-Lopez J, Rodriguez-Gallego C (2008) Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 122:368-374.

7. Peterslund NA, Koch C, Jensenius JC, Thiel S (2001) Association between deficiency of mannose binding lectin and severe infections after chemotherapy. Lancet 358:637-638.

8. Ytting H, Christensen IJ, Jensenius JC, Thiel S, Nielsen HJ (2005) Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunol Immunother 54:265-272.

9. Mullighan CG, Heatley SL, Danner S, Dean MM, Doherty K, Hahn U, Bradstock KF, Minchinton R, Schwarer AP, Szer J, Bardy PG (2008) Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 112:2120-2128.

10. Davies JC, Turner MW, Klein N (2004) Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 24:798-804.

11. Muhlebach MS, MacDonald SL, Button B, Hubbard JJ, Turner ML, Boucher RC, Kilpatrick DC (2006) Association between mannan-binding lectin and impaired lung function in cystic fibrosis may be age-dependent. Clin Exp Immunol 145:302-307.

12. Garred P, Voss A, Madsen HO, Junker P (2001) Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2:442-450.

13. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Valdimarsson H (2001) Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. J Rheumatol 28:728-734.

14. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N (2006) Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 21:2216-2222.

15. Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC (1999) Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol 49:193-196.

KIT 029 MBL Oligomer ELISA Kit 96 wells

WASH 029-30 25x Wash Solution Concentrate KIT 029 30 mL

WASH 029-250 25x Wash Solution Concentrate KIT 029 250 mL

* Please visit www.bioporto.com for availability in your country.

MBL Oligomer ELISA Kit

Diagnostics

Antibodies are listed according to their antigen by product area and with information about package size, applications, catalog number and conjugation, when applicable.

All the antibodies are protein-A or protein-G purified* and the unconjugated antibodies are delivered in a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.5 M sodium chloride and 15 mM sodium azide as preservative. Conjugated antibodies are delivered at a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.14 M NaCl and 15 mM sodium azide.

Cell biology

Specificity Pack Size Application Cat. No.

Collagen Type I (human, bovine, pig, sheep, dog, goat) 200 µg/1 mg EL, WB, IHC CSI 008-01

Collagen Type III (human, dog, rat, kangaroo) 200 µg/1 mg EL, WB, IHC CSI 007-01

Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) 200 µg/1 mg EL, WB, IHC CSI 006-01

Fibronectin (bovine) 200 µg/1 mg EL, WB, IHC, IP CSI 005-22

Fibronectin (bovine, human) 200 µg/1 mg EL, WB, IHC, IP CSI 005-32

200 µg/1 mg EL, WB, IHC, IP CSI 005-35

Fibronectin (bovine, human, chicken) 200 µg/1 mg EL, WB, IHC, IP CSI 005-17

Fibronectin (human) 200 µg/1 mg EL, WB HYB 051-05

Perlecan (bovine) 200 µg/1 mg EL, IHC, IP, AC CSI 001-71

200 µg/1 mg EL, IHC, IP, AC, WB CSI 001-74

200 µg/1 mg EL, IHC, IP CSI 001-76

Tetranectin (human) 200 µg/1 mg EL, WB, IHC HYB 130-11

200 µg/1 mg EL, WB HYB 130-13

200 µg/1 mg EL, WB HYB 130-14

Thrombospondin I (bovine) 200 µg/1 mg EL, IHC, IP CSI 002-65

Vitronectin (bovine, horse, rabbit) 200 µg/1 mg EL, IHC CSI 004-18

Vitronectin (bovine, sheep) 200 µg/1 mg EL, WB, IHC, AP CSI 004-27

Vitronectin (human) 200 µg/1 mg EL, WB, IHC CSI 003-02

200 µg/1 mg EL, WB CSI 003-23

Vitronectin (human, dog, cat, rabbit, bovine) 200 µg/1 mg EL, WB CSI 003-21

Vitronectin (human, dog, cat, sheep) 200 µg/1 mg EL, WB CSI 003-08

PerlecanCSI 001

Collagen I, III & VCSI 006CSI 007CSI 008

TetranectinHYB 130

VitronectinCSI 003CSI 004

Thrombo-spondin ICSI 002

FibronectinCSI 005HYB 051

Monoclonal antibodies

*Except HYB 189-01 which is provided as a culture supernatant12

Coagulation

Antithrombin III (human) 200 µg/1 mg EL, WB HYB 230-01

200 µg/1 mg EL, WB HYB 230-04

Antithrombin III (human, denatured) 200 µg/1 mg EL, WB HYB 228-12

Antithrombin III (human, native and denatured) 200 µg/1 mg EL, IHC HYB 228-08

APC–AAT complexes, neoepitope (human) 200 µg/1 mg EL ABS 001-07

Aprotinin 200 µg/1 mg EL, WB ABS 037-18

200 µg/1 mg EL ABS 037-21

200 µg/1 mg EL, WB ABS 037-35

Aprotinin, biotinylated 50 µg EL ABS 037-18B

D-dimer (human, dog) 200 µg/1 mg EL ABS 015-22

200 µg/1 mg EL ABS 015-28

D-dimer (human, dog), biotinylated 100 µg EL ABS 015-22B

Factor IX (human, Christmas factor) 200 µg/1 mg EL, WB HYB 133-01

200 µg/1 mg EL, WB HYB 133-09

Fibrinogen (human) 200 µg/1 mg EL, WB HYB 051-04

200 µg/1 mg EL, WB HYB 051-07

Hirudin 200 µg/1 mg EL, WB HYB 010-02

200 µg/1 mg EL, WB HYB 010-03

200 µg/1 mg EL HYB 010-05

200 µg/1 mg EL HYB 010-06

Protein C (human) 200 µg/1 mg EL, WB, IHC HYB 237-01

200 µg/1 mg EL, WB HYB 237-05

Protein S (human) 200 µg/1 mg EL HYB 232-11

Thrombin (human) 200 µg/1 mg EL, WB HYB 109-03

200 µg/1 mg EL, WB HYB 109-04

von Willebrand factor (human, vWf) 200 µg/1 mg EL HYB 060-01

200 µg/1 mg EL HYB 060-02

Collectins and related products

Collectin-43 (bovine, CL-43) 200 µg/1 mg EL, WB HYB 260-01

200 µg/1 mg EL, WB HYB 260-04

Conglutinin (bovine) 200 µg/1 mg EL HYB 263-02

Glycoprotein-340 (human, gp-340) 200 µg/1 mg EL, WB, IHC HYB 213-01

200 µg/1 mg EL, WB, IHC HYB 213-06

H-Ficolin (human) 200 µg/1mg EL RIG 334-01

H-Ficolin (human), biotinylated 100 µg EL RIG 334-01B

L-Ficolin (human) 200 µg/1 mg EL, WB ABS 005-16

200 µg/1 mg EL, WB ABS 005-19

M-Ficolin (human) 200 µg/1 mg EL, IHC ABS 036-01

200 µg/1 mg EL ABS 036-05

Surfactant protein A (human, hSP-A) 200 µg/1 mg EL, WB, IHC HYB 238-04

Surfactant protein A (human, hSP-A), biotinylated 100 µg EL HYB 238-04B

Collectins and related products (continued)

Surfactant protein D (human, hSP-D) 200 µg/1 mg EL, WB, IHC HYB 245-01

200 µg/1 mg EL, WB HYB 246-04

Surfactant protein D (human, hSP-D), biotinylated 100 µg EL HYB 246-04B

Complement

Complement component C1-inhibitor (human, C1-INH) 200 µg/1 mg EL HYB 288-02

200 µg/1 mg EL HYB 288-05

Complement component C1s (human, pro- and activated enzyme) 200 µg/1 mg EL ABS 002-09

200 µg/1 mg EL ABS 002-49

Complement component C2 (human) 200 µg/1 mg EL, WB HYB 050-04

200 µg/1 mg EL, WB HYB 050-05

200 µg/1 mg EL, WB HYB 050-08

Overview of the complement system. The name of the component and BioPorto Diagnostics' catalog number are shown in the blue boxes.

MBLKIT 029HYB 131

C1-INHHYB 288

C1sABS 002

C2HYB 050

C3HAV 004HYB 005

C3dHAV 003HYB 030

C5HYB 029

C9ABS 004

DIA 011

Factor BHAV 005

Factor DGAU 010GAU 00

M-FicolinABS 036

H-FicolinRIG 334

L-FicolinABS 005

Factor Ba/bHYB 008

ProperdinHYB 0393

C4HYB 162-04

C4bHYB 162-02

Factor HHYB 268GAU 018GAU 020

C3a/C3a (desArg)GAU 013GAU 017

Factor IHYB 061

Lysis or phagocytosis of the microorganism

C5 - C9Membrane attack complex

C3bBb3b

C1rC1s

C2b C4a

C4bC2aC4b2a

C4b2a3b

Classical Pathway Lectin Pathway Alternative Pathway

MBL/Ficolin

MASP-2

Carbohydrate

MASP-1

C3 (H2O)D

BaC3 (H2O) Bb

C3 (H2O) B

Properdin (Factor P)

Complement (continued)

Complement component C3 (human) 200 µg/1 mg EL, WB HAV 003-05

200 µg/1 mg EL, WB HYB 005-01

200 µg/1 mg EL, WB HYB 030-08

Complement component C3 (human), ß-chain genetic variant 200 µg/1 mg EL, WB HAV 004-01

Complement component C3 (rat) 200 µg/1 mg EL, IHC HYB 118-02

Complement component C3a/C3a desArg (human) 200 µg/1 mg EL, WB GAU 013-16

200 µg/1 mg EL, WB GAU 017-01

Complement component C3a/C3a desArg (human), biotinylated 100 µg EL GAU 017-01B

200 µg/1 mg EL, WB HYB 162-04

200 µg/1 mg EL, WB HYB 029-03

Complement component C5b-9 (human) 200 µg/1 mg EL, IHC DIA 011-01

Complement component C5b-9 (human), biotinylated 100 μg EL DIA 011-01B

Complement component C9 (human) 200 µg/1 mg EL, WB ABS 004-22

200 µg/1 mg EL ABS 004-53

Complement factor B (caiman) 200 µg/1 mg EL, WB KSK 002-01

Complement factor B (chicken) 200 µg/1 mg EL, WB HYB 022-03

Complement factor B (human) 200 µg/1 mg EL, WB HAV 005-02

200 µg/1 mg EL, WB HYB 008-02

200 µg/1 mg EL, WB HYB 008-04

200 µg/1 mg EL, WB HYB 008-06

Complement factor B (human), biotinylated 100 µg EL HYB 008-06B

Complement factor D (human) 200 µg/1 mg EL, WB GAU 008-01

200 µg/1 mg EL, WB GAU 010-04

Complement factor D (human), biotinylated 100 µg EL GAU 008-01B

Complement factor H (human, ß1H-globulin) 200 µg/1 mg EL, WB GAU 018-03

200 µg/1 mg EL, WB GAU 020-03

200 µg/1 mg EL, WB HYB 268-01

Complement factor H (human, ß1H-globulin), biotinylated 100 µg EL GAU 020-03B

100 µg EL HYB 268-01B

Complement factor I (human) 200 µg/1 mg EL, WB HYB 061-01

200 µg/1 mg EL, WB HYB 061-02

Mannan-binding lectin (chicken, MBL) 200 µg/1 mg EL, WB, IHC HYB 182-01

Mannan-binding lectin (human, horse, pig, MBL) 200 µg/1 mg EL HYB 131-14

Mannan-binding lectin (human, MBL) 200 µg/1 mg EL, WB, IHC HYB 131-01

200 µg/1 mg EL, WB HYB 131-10

200 µg/1 mg EL, WB HYB 131-11

Mannan-binding lectin (human, MBL), biotinylated 50 µg EL HYB 131-01B

Mannan-binding lectin (rat, MBL) 200 µg/1 mg EL HYB 131-18

Properdin (human) 200 µg/1 mg EL, WB HYB 039-04

200 µg/1 mg EL, WB HYB 039-06

Properdin (human), biotinylated 100 µg EL HYB 039-04B

Cytokines and hormones

α-Calcitonin gene-related peptide (α-CGRP) 200 µg/ 1mg EL, IHC ABS 026-04

200 µg/ 1mg EL, IHC ABS 026-05

Adrenomedulin (human) 200 µg/1 mg EL ABS 027-01

Chorionic gonadotrophin (human, hCG) 200 µg/1 mg EL, WB HYB 093-04

200 µg/1 mg EL, WB HYB 093-05

200 µg/1 mg EL, WB HYB 093-09

Estradiol-17β 200 µg/1 mg EL HYB 057-02

ABS 033-04 and ABS 033-10 both react with the free N-terminus of GLP-1(7-36)amide or GLP-1(7-37), showing 0.25% or less cross-reactivity with GLP-1(1-36)amide or GLP-1(9-36)amide. ABS 033-10 shows about 50% cross-reactivity with the closely related N-terminus of exendin-4, whereas ABS 033-04 does not cross-react significantly with exendin-4.

ABS 044-49 and ABS 044-53 react with the N-terminus of GLP-1 (GLP-1(9-36)amide and GLP-1(9-37)) and show a lowlevel of cross-reactivity with the active forms of GLP-1 (GLP-1(7-36)amide and GLP-1(7-37)).

ABS 046-03 binds GLP-1(1-37), GLP-1(7-37) and GLP-1(9-37). Two different ELISA sandwich setups can be made for measuring non-amidated GLP-1 forms: the first uses ABS 046-03 as a capture antibody with ABS 033-10B as a bioti-nylated detection antibody cross-reacting about 5% with C-terminally amidated GLP-1. The second combination uses ABS 046-03B as a biotinylated detection antibody and HYB 147-12 as a capture antibody cross-reacting about 16% with C-terminally amidated GLP-1.

HYB 147-06 reacts with the amidated C-terminus of GLP-1(7-36)amide and GLP-1(1-36)amide, but not the corresponding unamidated forms. This antibody can be used as capture antibody in sandwich ELISA using biotinylated HYB 147-12 as detection antibody.

HYB 147-08, HYB 147-12 and HYB 147-13 all react with different overlapping mid-molecular epitopes found on all forms of GLP-1.

HYB 011-05 binds to an epitope on the 1-6 portion of the GLP-1(1-36)amide. It does not react with the two active forms of GLP-1, GLP-1(7-36)amide and GLP-1(7-37).

Glucagon-like peptide-1 (C-terminal amidated)

HYB 011-05 HYB 147-06 ABS 046-03

C-terminus C-terminusN-terminal extension

N-terminus

36 amide

HYB 147-08HYB 147-12HYB 147-13

ABS 033-04ABS 033-10

ABS 044-49ABS 044-53

GLP-1 Extended form GLP-1 Active form GLP-1 Metabolite

HYB 011-05 HYB 147-06

C-terminusN-terminal extension

N-terminus

36(amide)1 6 7

36(amide)7

36(amide)9

HYB 147-08HYB 147-12HYB 147-13

ABS 033-04ABS 033-10

HYB 011-05 HYB 147-06

N-terminus

36(amide)1 6 7

36(amide)7

36(amide)9

HYB 147-08HYB 147-12HYB 147-13

ABS 033-04ABS 033-10

HYB 011-05 HYB 147-06

N-terminus

36(amide)1 6 7

36(amide)7

36(amide)9

HYB 147-08HYB 147-12HYB 147-13

ABS 033-04ABS 033-10

Cytokines and hormones (continued)

Exendin-4 200 µg/1 mg EL ABS 012-20

200 µg/1 mg EL ABS 012-23

200 µg/1 mg EL ABS 012-24

200 µg/1 mg EL ABS 012-35

Exendin-4, biotinylated 50 µg EL ABS 012-23B

50 µg EL ABS 012-35B

Gastric inhibitory polypeptide (human, GIP) 200 µg/1 mg EL, IHC ABS 021-04

200 µg/1 mg EL ABS 021-05

Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) 200 µg/1 mg EL HYB 011-05

Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) 200 μg/1 mg EL, IHC HYB 147-06

Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific), biotinylated

50 µg EL HYB 147-06B

Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific)

200 μg/1 mg EL ABS 033-04

200 μg/1 mg EL ABS 033-10

Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific), biotinylated

Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific)

200 μg/1 mg EL ABS 044-49

200 μg/1 mg EL ABS 044-53

Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) 200 μg/1 mg EL, WB HYB 147-08

200 μg/1 mg EL, WB, IHC HYB 147-12

200 μg/1 mg EL, WB HYB 147-13

Glucagon-like peptide-1 (GLP-1, Mid-molecule specific), biotinylated 50 µg EL HYB 147-08B

Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific) 200 μg/1 mg EL ABS 046-03

Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminalspecific), biotinylated

Glucagon-like peptide-2 (human, GLP-2) 200 μg/1 mg EL HYB 006-02

Leptin 200 µg/1 mg EL, IHC ABS 022-03

200 µg/1 mg EL ABS 022-06

200 µg/1 mg EL ABS 022-11

Leptin, biotinylated 100 µg EL ABS 022-11B

Neuropeptide Y (human, rat, mouse, NPY) 200 µg/1 mg EL, IHC ABS 028-08

Pancreatic polypeptide (human, PP) 200 µg/1 mg EL ABS 030-06

Peptide histidine-methionine (human, PHM) 200 µg/1 mg EL ABS 020-03

Peptide YY (human, PYY) 200 µg/1 mg EL, IHC ABS 029-01

Tumor necrosis factor α (human, TNF-α) 200 µg/1 mg EL HYB 141-08

200 µg/1 mg EL HYB 141-09

Vasoactive intestinal peptide (human, bovine, porcine, rat, VIP) 200 µg/1 mg EL ABS 023-02

Enzymes

Alkaline phosphatase (AP) 200 µg/1 mg EL HYB 252-08

Trypsin (human) 200 µg/1 mg EL, WB HYB 021-03

200 µg/1 mg EL, WB HYB 021-08

Trypsin (human), biotinylated 100 µg EL HYB 021-03B

Marker molecules

α-Fetoprotein (human, AFP) 200 µg/1 mg EL HYB 097-04

200 µg/1 mg EL HYB 097-06

200 µg/1 mg EL HYB 097-07

200 µg/1 mg EL HYB 097-08

200 µg/1 mg EL HYB 097-09

Acetylcholinesterase (bovine brain, AChE) 200 µg/1 mg EL, WB HYB 101-03

Acetylcholinesterase (human brain, AChE) 200 µg/1 mg EL, WB HYB 111-05

Acetylcholinesterase (human brain, bovine brain, AChE) 200 µg/1 mg EL, WB HYB 190-01

Amyloid-β peptide (human) 200 µg/1 mg EL HYB 310-03

200 µg/1 mg EL HYB 310-04

200 µg/1 mg EL HYB 310-07

200 µg/1 mg EL, AP HYB 310-08

Butyrylcholinesterase (human, BtChE) 200 µg/1 mg EL HAH 002-01

Neutrophil gelatinase-associated lipocalin (dog, NGAL) 200 µg/1 mg EL, WB ABS 047-14

200 µg/1 mg EL, WB ABS 047-17

Neutrophil gelatinase-associated lipocalin (dog, NGAL), biotinylated 50 μg EL ABS 047-14B

Neutrophil gelatinase-associated lipocalin (human, NGAL) 200 µg/1 mg EL, WB ABS 038-04

200 µg/1 mg EL, WB ABS 038-14

200 µg/1 mg EL, WB ABS 038-15

200 µg/1 mg EL, WB ABS 038-26

200 µg/1 mg EL, WB HYB 211-05

Neutrophil gelatinase-associated lipocalin (human, NGAL), biotinylated 50 µg EL HYB 211-01B

Neutrophil gelatinase-associated lipocalin (monkey, NGAL) 200 µg/1 mg EL ABS 038-23

Neutrophil gelatinase-associated lipocalin (mouse, NGAL) 200 µg/1 mg EL, WB ABS 043-10

200 µg/1 mg EL, WB ABS 043-29

Neutrophil gelatinase-associated lipocalin (mouse, NGAL), biotinylated 50 µg EL ABS 043-29B

Neutrophil gelatinase-associated lipocalin (pig, NGAL) 200 µg/1 mg EL, WB ABS 048-17

200 µg/1 mg EL ABS 048-28

Neutrophil gelatinase-associated lipocalin (pig, NGAL), biotinylated 50 μg EL ABS 048-28B

Neutrophil gelatinase-associated lipocalin (rat, NGAL) 200 µg/1 mg EL, IHC ABS 039-08

200 µg/1 mg EL, WB ABS 039-32

Neutrophil gelatinase-associated lipocalin (rat, NGAL), biotinylated 50 µg EL ABS 039-32B

Placental protein 14 (human, PP14, glycodelin A) 200 µg/1 mg EL, IHC BTE 001-13

200 µg/1 mg EL, IHC BTE 001-16

Pregnancy-associated plasma protein A (human, PAPP-A) 200 µg/1 mg EL, IHC ABS 006-01

200 µg/1 mg EL ABS 006-24

Procollagen type I C-terminal propeptide (human, PICP) 200 µg/1 mg EL BTE 002-04

200 µg/1 mg EL BTE 002-08

200 µg/1 mg EL BTE 002-18

200 µg/1 mg EL BTE 002-32

Procollagen type IIA N-terminal propeptide (human, PIIANP) 200 µg/1 mg EL, IHC BTE 003-02

Microbiology

Clostridium botulinum E toxoid (Botulin E toxoid) 200 µg/1 mg EL HAV 001-02

200 µg/1 mg EL HAV 001-06

Clostridium tetani toxoid (Tetanus toxoid) 200 µg/1 mg EL HYB 278-01

200 µg/1 mg EL HYB 278-10

200 µg/1 mg EL HYB 278-14

200 µg/1 mg EL HYB 278-15

200 µg/1 mg EL HYB 278-17

Corynebacterium diphtheriae toxoid (Diphtheria toxoid) 200 µg/1 mg EL HYB 123-05

200 µg/1 mg EL, WB HYB 123-09

Influenza A virus 200 µg/1 mg EL, WB HYB 156-01

200 µg/1 mg EL, WB HYB 156-02

Influenza A virus, biotinylated 100 μg EL HYB 156-01B

100 μg EL HYB 156-02B

Influenza B virus 200 µg/1 mg EL HYB 116-01

200 µg/1 mg EL, WB HYB 116-02

200 µg/1 mg EL, WB HYB 116-03

Influenza B virus, biotinylated 100 μg EL HYB 116-03B

Mycobacterium tuberculosis, Ag85 200 µg/1 mg EL, WB HYT 27

Mycobacterium tuberculosis, ESAT-6 200 µg/1 mg EL, WB HYB 076-08

Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) 200 µg/1 mg EL, WB HBT 10

Nitrobacter hamburgensis nitrite oxidoreductase 200 µg/1 mg EL, WB, IHC HYB 153-01

Pneumolysin 200 µg/1 mg EL, WB HYB 041-01

Poliovirus type 1 200 µg/1 mg EL HYB 295-15

200 µg/1 mg EL HYB 295-17

200 µg/1 mg EL HYB 294-06

200 µg/1 mg EL HYB 300-06

Streptolysin 200 µg/1 mg EL HAB 003

Miscellaneous

Amodiaquine 200 µg/1 mg EL HYB 320-04

Atrazine 200 µg/1 mg EL HYB 225-01

Biotin 200 µg/1 mg EL, WB HYB 212-01

Chloroquine 200 µg/1 mg EL HYB 317-01

Gliadin peptide 200 µg/1 mg EL HYB 314-01

200 µg/1 mg EL HYB 314-02

Immunoglobulin heavy chain (chicken, IgY) 200 µg/1 mg EL, WB HYB 208-03

Immunoglobulin light chain (rat, κ chain) 200 µg/1 mg EL, AC MARK 1

MHC class I α chain (chicken) 200 µg/1 mg WB KSK 001-03

MHC class II β chain (chicken) 200 µg/1 mg WB, IHC, AP, FC KSK 001-02

Miscellaneous (continued)

Ovalbumin (chicken) 200 µg/1 mg EL, IP HYB 099-01

200 µg/1 mg EL, IP HYB 099-02

200 µg/1 mg EL HYB 099-09

200 µg/1 mg EL HYB 099-11

Ovalbumin (chicken, denatured) 200 µg/1 mg EL, WB HYB 094-05

200 µg/1 mg EL, WB HYB 094-06

200 µg/1 mg EL, WB HYB 094-07

Thioguanine (2-amino-6-mercaptopurine) 200 µg/1 mg EL HYB 125-03

200 µg/1 mg EL HYB 138-02

200 µg/1 mg EL HYB 144-04

Oncology

Plasminogen activator inhibitor type I (human, PAI-1) 200 µg/1 mg EL, WB, IHC, AP MON I-1

200 µg/1 mg EL, WB, IHC, AP MON I-2

200 µg/1 mg EL, WB, IHC MON I-3

Tissue plasminogen activator (human, tPA) 200 µg/1 mg EL, WB, IHC MON T-1

Urokinase plasminogen activator (human, uPA) 200 µg/1 mg EL, WB, IHC MON U-5

200 µg/1 mg EL, WB, IHC MON U-6

200 µg/1 mg EL, WB, IHC MON U-12

200 µg/1 mg EL, WB, IHC, FC MON U-16

Urokinase plasminogen activator receptor (human, uPAR) 200 µg/1 mg EL, WB MON R-3

200 µg/1 mg EL, WB, IHC, FC MON R-4

200 µg/1 mg EL, WB, IHC MON R-5

Other blood proteins

α1-Antitrypsin (human, α1-AT) 200 µg/1 mg EL, WB HYB 185-02

α1-Antitrypsin (human, α1-AT, native and denatured) 200 µg/1 mg EL, WB HYB 191-01

Albumin, bovine serum (BSA) 200 µg/1 mg EL, WB HYB 267-01

Albumin, bovine serum (BSA, denatured) 200 µg/1 mg EL HYB 261-02

Albumin, human serum (HSA) 200 µg/1 mg EL, WB HYB 192-01

200 µg/1 mg EL, WB HYB 192-02

200 µg/1 mg EL, WB HYB 193-05

Albumin, human serum (HSA, denatured) 200 µg EL, WB HYB 189-01*

200 µg/1 mg EL, WB HYB 189-09

Apolipoprotein A-1 (human) 200 µg/1 mg EL, WB HYB 069-01

Apolipoprotein B (human) 200 µg/1 mg EL, WB HYB 069-02

200 µg/1 mg EL HYB 069-03

200 µg/1 mg EL HYB 069-04

β2-Microglobulin (caiman) 200 µg/1 mg WB KSK 003-01

β2-Microglobulin (human) 200 µg/1 mg EL, AP HYB 290-03

* Only available as a culture supernanant20

Other blood proteins (continued)

Gc-globulin (human) 200 µg/1 mg EL, WB HYB 249-01

200 µg/1 mg EL, WB HYB 249-02

200 µg/1 mg EL HYB 249-05

200 µg/1 mg EL HYB 249-10

Gc-globulin (human), biotinylated 50 µg EL HYB 249-01B

Gelsolin (human) 200 µg/1 mg EL, WB ABS 017-20

Haptoglobin (human) 200 µg/1 mg EL HYB 170-06

Hemopexin (human) 200 µg/1 mg EL, WB ABS 013-04

200 µg/1 mg EL ABS 013-32

Hemopexin (human), biotinylated 100 µg EL, WB ABS 013-04B

100 µg EL ABS 013-32B

MDA treated low-density lipoprotein (human, LDL) 200 µg/1 mg EL, WB HYB 262-01

200 µg/1 mg EL, WB HYB 262-03

200 µg/1 mg EL, WB HYB 262-04

200 µg/1 mg EL, WB HYB 262-05

Sera and antigens

Specificity Pack Size Cat. No.

EcoR1 (IgG/k control antibody) 1 mg HYB 098-08

Human IgE (non-immune), without azide 100 µg/1 mg DIA HE1

Human IgE (non-immune), with azide 100 µg/1 mg DIA HE1A

Human IgE (non-immune), biotinylated 100 µg DIA HE1B

MBL standard serum (human) - 1000 (AU) 1 mL SER 101

MBL oligomer deficient serum, B/B genotype (human) 1 mL SER 102

SDS-PAGE (16%).

Lane 1: Shows molecular weight markers.

Lane 2: DIA HE1 purified human IgE, 185 kDa.

Lane 3: IgE, purified from serum from a myeloma patient.

The DIA HE1 IgE preparation is an affinity-purified, fully human IgE antibody with kappa light chains. The IgE is produced in vitro from a monoclonal hybridoma. This unique source guarantees freedom from contamination by other immunoglobulin isotypes.

Due to its very low batch-to-batch variation, this antibody is suitable as a standard in quantitative IgE assays, used in the field of allergy treatment and diagnostics. Other applications include research in immunochemistry and cellular immunology.

Human IgE (non-immune) DIA HE1

AC Affinity chromatography

AP Affinity purification

EL Enzyme-linked immunosorbent assay (ELISA)

FC Flow cytometry

IHC Immunohistochemistry

IP Immunoprecipitation

WB Western blotting

Abbreviations

Aα-Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18α1-Antitrypsin (human, α1-AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20α1-Antitrypsin (human, α1-AT, native and denatured) . . . . . . . . 20α-Calcitonin gene-related peptide (α-CGRP) . . . . . . . . . . . . . . . 16Acetylcholinesterase (bovine brain, AChE) . . . . . . . . . . . . . . . . . . 18Acetylcholinesterase (human brain, AChE). . . . . . . . . . . . . . . . . . 18Acetylcholinesterase (human brain, bovine brain, AChE) . . . . . 18Activated protein C-protein C inhibitor (APC-PCI) . . . . . . . . . . . . 8Activated protein C-α1-antitrypsin, neoepitope (human) . . . . . 13Adrenomedulin (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16Albumin, bovine serum (BSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Albumin, bovine serum (BSA, denatured) . . . . . . . . . . . . . . . . . . 20Albumin, human serum (HSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Albumin, human serum (HSA, denaturated) . . . . . . . . . . . . . . . . 20Alkaline phosphatase (AP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172-amino-6-mercaptopurine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Amodiaquine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Amyloid-β peptide (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18Antithrombin III (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Antithrombin III (human, denatured) . . . . . . . . . . . . . . . . . . . . . . . . 13Antithrombin III (human, native and denatured). . . . . . . . . . . . . . 13APC-AAT complexes, neoepitope (human). . . . . . . . . . . . . . . . . . 13APC-PCI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8Apolipoprotein A-1 (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Apolipoprotein B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Aprotinin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Atrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Bβ1H-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15β2-Microglobulin (caiman). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20β2-Microglobulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Biotin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Botulin E toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19BSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20BSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Butyrylcholinesterase (human, BtChE) . . . . . . . . . . . . . . . . . . . . . 18

CCalcitonin-gene related peptide (human, CGRP) . . . . . . . . . . . . 16Chloroquine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Chorionic gonadotrophin (human, hCG) . . . . . . . . . . . . . . . . . . . . 16Christmas factor (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Clostridium botulinum E toxoid (Botulin E toxoid) . . . . . . . . . . . 19Clostridium tetani toxoid (Tetanus toxoid) . . . . . . . . . . . . . . . . . . 19Coagulation factor IX (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Collagen Type I (human, bovine, pig, sheep, dog, goat) . . . . . . 12Collagen Type III (human, dog, rat, kangaroo) . . . . . . . . . . . . . . 12Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Collectin-43 (bovine, CL-43) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Complement component C1-inhibitor (human, C1-INH) . . . . . 14Complement component C1s (human, pro- and activated enzyme) . . . . . . . . . . . . . . . . . . . . . . . 14Complement component C2 (human) . . . . . . . . . . . . . . . . . . . . . . 14Complement component C3 (human) . . . . . . . . . . . . . . . . . . . . . . 15Complement component C3 (human), β-chain genetic variant . 15

Complement component C3 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . 15Complement component C3a/C3a desArg (human) . . . . . . . . . 15Complement component C4 (human) . . . . . . . . . . . . . . . . . . . . . . 15Complement component C5 (human) . . . . . . . . . . . . . . . . . . . . . . 15Complement component C5b-9 (human) . . . . . . . . . . . . . . . . . . . 15Complement component C9 (human) . . . . . . . . . . . . . . . . . . . . . . 15Complement factor B (caiman). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Complement factor B (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Complement factor B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Complement factor D (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Complement factor H (human, ß1H-globulin) . . . . . . . . . . . . . . . . 15Complement factor I (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Conglutinin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Corynebacterium diphtheriae toxoid (Diphtheria toxoid) . . . . . 19

DD-dimer (human, dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13DBP (human, Vitamin-D binding protein). . . . . . . . . . . . . . . . . . . . 21Diphtheria toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Dog NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

EEcoR1 (IgG/k control antibody) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Estradiol-17β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16Exendin-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

FFactor IX (human, Christmas factor) . . . . . . . . . . . . . . . . . . . . . . . . 13Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18Fibrinogen (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Fibronectin (bovine). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Fibronectin (bovine, human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Fibronectin (bovine, human, chicken). . . . . . . . . . . . . . . . . . . . . . . 12Fibronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Ficolin-H (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Ficolin-L (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Ficolin-M (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

GGastric inhibitory polypeptide (human, GIP). . . . . . . . . . . . . . . . . 17Gc-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Gelsolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Gliadin peptide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) . . . . . . . 16, 17Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) . . . . . . . . . . . . . . . . . 16, 17Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific) . 16, 17Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific). . . . . . . . . . . . . . . . . . 16, 17Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) . . 16, 17Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific). . . . . . . . . . . . . . . . . . . . . . . . . . 16, 17Glucagon-like peptide-2 (human, GLP-2) . . . . . . . . . . . . . . . . 16, 17Glycodelin A (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18Glycoprotein-340 (human, gp-340). . . . . . . . . . . . . . . . . . . . . . . . . 13

Alphabetical product index

ELISA kits and monoclonal antibodies listed by specificity

Diagnostics

Alphabetical index

HHaptoglobin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Hemopexin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21hCG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16H-Ficolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13HNL (human neutrophil lipocalin) . . . . . . . . . . . . . . . . . . . . . . 4, 7, 18HSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20HSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20hSP-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13hSP-D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14Human IgE (non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

IIgE (human, non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21IgG/k control antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Immunoglobulin heavy chain (chicken, IgY) . . . . . . . . . . . . . . . . . 19Immunoglobulin light chain (rat, κ chain) . . . . . . . . . . . . . . . . . . . . 19Influenza A virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Influenza B virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

LLDL, (human, MDA-treated) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21Leptin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17L-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Lipocalin-2 (dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Lipocalin-2 (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 7, 18Lipocalin-2 (monkey) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Lipocalin-2 (mouse) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Lipocalin-2 (pig) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Lipocalin-2 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

MMannan-binding lectin (chicken, MBL). . . . . . . . . . . . . . . . . . . . . . 15Mannan-binding lectin (human, horse, pig, MBL) . . . . . . . . . . . . 15Mannan-binding lectin (human, MBL) . . . . . . . . . . . . . . . . . . . 10, 15Mannan-binding lectin (rat, MBL) . . . . . . . . . . . . . . . . . . . . . . . . . . 15MBL standard serum (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21MBL Oligomer deficient serum (human) . . . . . . . . . . . . . . . . . . . . 21MDA treated low-density lipoprotein (human, LDL) . . . . . . . . . . 21M-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13MHC class I α chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19MHC class II β chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Monkey NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Mouse NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Mycobacterium tuberculosis, Ag85 . . . . . . . . . . . . . . . . . . . . . . . . 19Mycobacterium tuberculosis, ESAT-6 . . . . . . . . . . . . . . . . . . . . . . 19Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) . . 19

NNeuropeptide Y (human, rat, mouse, NPY). . . . . . . . . . . . . . . . . . 17NGAL (dog, neutrophil gelatinase-associated lipocalin) . . . . 7, 18NGAL (human, neutrophil gelatinase-associated lipocalin) . 4, 7, 18NGAL (monkey, neutrophil gelatinase-associated lipocalin). . . .7, 18NGAL (mouse, neutrophil gelatinase-associated lipocalin). . . . .7, 18NGAL (pig, neutrophil gelatinase-associated lipocalin). . . . . 7, 18NGAL (rat, neutrophil gelatinase-associated lipocalin) . . . . . 7, 18Nitrobacter hamburgensis nitrite oxidoreductase. . . . . . . . . . . . 19

OOvalbumin (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Ovalbumin (chicken, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

PPAI-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20Pancreatic polypeptide (human, PP) . . . . . . . . . . . . . . . . . . . . . . . 17Peptide histidine-methionine (human, PHM) . . . . . . . . . . . . . . . . 17Peptide YY (human, PYY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17Perlecan (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Pig NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18Placental protein 14 (human, PP14, glycodelin A) . . . . . . . . . . . . 18Plasminogen activator inhibitor type 1 (human, PAI-1). . . . . . . . 20Pneumolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Poliovirus type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Poliovirus type 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Poliovirus type 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Pregnancy-associated plasma protein A (human, PAPP-A) . . . 18Procollagen type I C-terminal propeptide (human, PICP) . . . . . 18Procollagen type IIA N-terminal propeptide (human, PIIANP) . 18Properdin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15Protein C (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Protein S (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

RRat NGAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

SStreptolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Surfactant protein A (human, hSP-A) . . . . . . . . . . . . . . . . . . . . . . . 13Surfactant protein D (human, hSP-D). . . . . . . . . . . . . . . . . . . . . . . 14Siderocalin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 5, 6, 7, 18

TTetanus toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19Tetranectin (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Thioguanine (2-amino-6-mercaptopurine) . . . . . . . . . . . . . . . . . . 20Thrombin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Thrombospondin I (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Tissue plasminogen activator (human, tPA) . . . . . . . . . . . . . . . . . 20Trypsin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17Tumor necrosis factor α (human, TNF-α). . . . . . . . . . . . . . . . . . . . 17

UUrokinase plasminogen activator (human, uPA) . . . . . . . . . . . . . 20Urokinase plasminogen activator receptor (human, uPAR) . . . 20

VVasoactive intestinal peptide (human, bovine, porcine, rat, VIP) . . . . . . . . . . . . . . . . . . . . . . . . . . 17Vitamin-D binding protein (human) . . . . . . . . . . . . . . . . . . . . . . . . . 21Vitronectin (bovine, horse, rabbit) . . . . . . . . . . . . . . . . . . . . . . . . . . 12Vitronectin (bovine, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Vitronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12Vitronectin (human, dog, cat, rabbit, bovine) . . . . . . . . . . . . . . . . 12Vitronectin (human, dog, cat, sheep) . . . . . . . . . . . . . . . . . . . . . . . 12von Willebrand factor (human, vWf) . . . . . . . . . . . . . . . . . . . . . . . . 13

Alphabetical index

Diagnostics

Ordering information

Products should be ordered from your local BioPorto Diagnostics distributor. If there is no distributor in your country, please order directly from BioPorto Diagnostics.

BioPorto Diagnostics A/SGrusbakken 8DK-2820 GentofteDenmark

VAT number DK-1864 5882

Phone (+45) 4529 0000Fax (+45) 4529 0001

Mail info@bioporto.comWeb www.bioporto.com

Terms and conditionsReturnsNo returns can be accepted without prior written approval by the ordering channel (distributor or BioPorto Diagnostics). Only unopened merchandise that has been handled and stored as prescribed can be returned. No return of custom manufactured products will be authorized if the product meets the specifications agreed upon prior to shipment.

Alternate rightBioPorto Diagnostics reserves the right to change product specifications (e.g. buffer system) to maximize product quality.

StorageDirections given on an individual datasheet or label are an integral part of these terms and conditions and must be strictly followed.

Reservation of titleUnless otherwise marked, all products are for research use or further manufacture only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. Product codes: GAU*, MON* and DIA 011-01B, are not for further manufacture either.

CE-marked products comply with EU Directive 98/79/EC on in vitro diagnostic medical devices and are for in vitro diagnostic use in countries that recognize this legislation.

The NGAL Rapid ELISA Kit (KIT 037) is for in-vitro diagnostic (IVD) use in selected countries. Please visit www.bioporto.com for availability in your country.

The MBL Oligomer ELISA Kit (KIT 029) is for in-vitro diagnostic (IVD) use in selected countries. Please visit www.bioporto.com for availability in your country.

All products remain the property of BioPorto Diagnostics A/S until full payment has been received.

The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics be responsible for loss of profits or indirect consequential losses resulting from use of its products.

For more informationContact your local distributor or BioPorto Diagnostics.

Diagnostics

Ordering

Distributors

BelgiumImTec Diagnostics N.V.Hortensiastraat 12 2020 Antwerpen Phone: +32 3 225 1139 Fax: +31 297 56 34 58 E-mail: info@imtec.be

BrazilScience Pro Rua Rafael Correa Sampaio, 1186 09541-250 São Caetano do Sul - SP Phone: +55 11 4221 6609Fax: +55 11 4224 1388 E-mail: sciencepro@sciencepro.com.brWeb: www.sciencepro.com.br

CanadaAFFINITY Diagnostics Corp.288 Wildcat RoadToronto, Ontario M3J 2N5 Toll Free: +1 877 370 6300 Phone: +1 416 650 6300 Fax: +1 416 650 5990 E-mail: info@affinitydiagnostics.ca Web: www.affinitydiagnostics.ca

Cedarlane Laboratories Ltd.4410 Paletta Court Burlington, Ontario, L7L 5R2Toll Free: +1 800 268 5058 Phone: +1 289 288 0001 Fax: +1 289 288 0020 E-mail: general@cedarlanelabs.comWeb: www.cedarlanelabs.com/Canada

Czech RepublicLAB MARK a.s.Pod Cihelnou 23161 00 Praha 6Phone: +420 233 335 548Fax: +420 233 335 930E-mail: labmark@labmark.czWeb: www.labmark.cz

ChinaShanghai, Zhejiang, Jiangsu, Jiangxi, Anhui and Henan provincesSeebio Biotech, Inc.11-502, No.299 Bi Sheng Road (The First Shanghai Centre)Zhang Jiang Hi-Tech ZoneShanghai 201204Free call: 800 988 1820Phone: +86 21 5027 2975 +86 21 5027 2976Fax: +86 21 5027 2979E-mail: service@seebio.cnWeb: www.cxbio.comWeb: www.seebio.cn

Beijing, Tianjin, Hebei, Shanxi, Shandong, Heilongjiang, Jilin, Liaoning, Neimenggu, Xinjiang, Qinghai, Gansu, Ningxia, Shan’xi and Hong Kong provincesNeoBioscience Technology Company17C2-2, Unit E, Peng An Building, No.20 Yuanda RoadHaidian District, Beijing 100089Phone: +86 108859 4029 ext 804Fax: +86 10 8859 4129 ext 808E-mail: info@neobioscience.comWeb: www.neobioscience.com

Guangdong, Guangxi, Fujian and Hainan provincesGuangzhou Dahui Biotech Co. Ltd.Room 2808, Floor 28, Huihua Commerce and Trade BuildingNo.80 Xianlie Zhong RoadGuangzhou, Guangdong Province 510070Phone: +86 20 3763 6952 +86 20 3763 6935Fax: +86 20 3763 6953Web: www.dahuibio.com

FranceSociété COGER 79, Rue des Morillons FR-75015 Paris Phone: +33 145 33 67 17 Fax: +33 145 32 71 04 E-mail: info@coger.frWeb: www.coger.fr

Germanydianova GmbHWarburgstraße 45D-20354 HamburgPhone: +49 40 45 06 70Fax: +49 40 45 06 74 90E-mail: info@dianova.deWeb: www.dianova.de

GreeceAnachem9 Adrianiou Str.11525 N. Psihiko, AthensPhone: +30 210 67 41 765Fax: +30 210 67 41 278E-mail: info@anachem.gr Web: www.anachem.gr

IndiaTamil Nadu, Andhra Pradesh, Gujarat, Goa, Kerala, Karnataka, Maharashtra, Puducherry, Andamans, Nicobar and Lakshwadeep CPC Diagnostics Pvt. Ltd. No.9, 5th floor, Gokul Tower 9&10 C.P. Ramaswamy Road Alwarpet, Chennai - 600 018 Phone: +91 44 24993989 Fax: +91 44 24993357 E-mail: immuno@cpcdiagnostics.in Web: www.cpcdiagnostics.in

Dehli, Punjab, Haryana, U.P., Bihar, Jharkhand, West Bengal, J&K, H. P., Uttarakhand, Assam, A.P., Rajasthan, Madhya Pradesh, Chhattisgarh and Orissa Immunoshop India Pvt. Ltd. 309, Raheja Arcade, Sector-11,CBD, BelapurNavi Mumbai - 400614 Phone: +91 22 27566891 +91 22 27566892Fax: +91 27 566893 E-mail: info@immunoshop.com Web: www.immunoshop.com

IndonesiaPT. Genetika Science Indonesia (An affiliate of vCell Science Pte.) Jln. Keadilan Raya No. 17FJakarta Barat 11130Phone: +62 21 6345687 Fax: +62 21 6345689 E-mail: info@ptgenetika.com Web: www.ptgenetika.com

Distributors

Diagnostics

IranMahdia Teb Zist Co. Ltd.No.28 Ghanbare Jafari (180E)Tehranpars, Tehran - 1655937311Phone: +98 21 7729 7231Mobile: +98 912 383 3420Fax: +98 21 7787 8790E-mail: Info@mahdiateb.com

IrelandCaltag-Medsystems Ltd. Botyl Road, Botolph Claydon MK18 2LR Buckingham Free call: 800 279 9113 Phone: +44 (0)1296 715459 Fax: +44 (0)1296 715718 E-mail: sales@caltagmedsystems.co.ukWeb: www.caltagmedsystems.co.uk

IsraelAlmog Diagnostic and Medical Equipment Ltd.P.O. Box 349 Shoham 60850Phone: +972 3 9773390 Fax: +972 3 9773391 E-mail: info@almog.co.ilWeb: www.almog.co.il

ItalyBio Exe SRL Via Albere 132 IT-37137 Verona Phone: +39 045 8904496 Fax: +39 045 8625313 E-mail: info@bioexe.itWeb: www.bioexe.it

JapanFunakoshi Co., Ltd.9-7 Hongo, 2-chome, Bunkyo-ku 113-003 TokyoPhone: +81 3 5684 1620Fax: +81 3 5684 1775E-mail: info@funakoshi.co.jpWeb: www.funakoshi.co.jp

KoreaDong-In Biotech Co., Ltd. 19-9 Geoyeodong Songpaku, Seoul 138-110 Phone: +82 2 2043 7375Fax: +82 2 431 0645 E-mail: info@donginbiotech.co.krWeb: www.donginbiotech.co.kr

KOMA Biotech Inc. 301, Gayang Technotown, #1487 Gayang 3 dong, Gangseo-gu Seoul 157-793Phone: +82 2 579 8787 Fax: +82 2 578 7042 E-mail: koma@komabiotech.co.kr Web: www.komabiotec.co.kr

Kuwaitbioactiva diagnostica Louisen Str. 11 D-61348 Bad Homburg - Germany Phone: +49 6172 17102 0 Fax: +49 6172 17102 29 E-mail: bioactiva@bioactiva.deWeb: www.bioactiva.de

LuxembourgImTec Diagnostics N.V.Hortensiastraat 12 2020 Antwerpen, Belgium Phone: +32 3 225 1139 Fax: +31 297 56 34 58 E-mail: info@imtec.be

MalaysiaAxon Scientific Sdn Bhd (An affiliate of vCell Science Pte.) No. 13-4, Jalan SP2/1Taman Serdang Perdana43300 Seri KembanganSelangor DEPhone: +603 89451482Fax: +603 89419421E-mail: info@axonscientific.comWeb: www.axonscientific.com

NetherlandsITK diagnostics BV Joh. Enschedeweg 13 NL-1422 DR Uithoorn Phone: +31 297 56 88 93 Fax: +31 297 56 34 58 E-mail: info@itk.nlWeb: www.itk.nl

PakistanFriends Scientific Corporation3-B Ali Continental1-Mozang RoadLahore-54000Phone: +92 42 7236176 +92 42 7350926Fax: +92 42 7321500E-mail: friends1@wol.net.pk

PolandDRG MedTek Sp. zo.oul. Wita Stwosza 2402-661 WarszawaPhone: +48 22 847 82 44 +48 22 847 83 75Fax: +48 22 843 72 74E-mail: office@drgmedtek.plWeb: www.drgmedtek.pl DRG MedTek South Polandul. Piotra Skargi 2844-100 GliwiceE-mail: drg_wj@medianet.plWeb: www.drg.alpha.pl

PortugalINODIA Inovação Diagnóstica e Médica, Lda.Rua General Silva, nº41 A 2º Esq 1800-208 Lisbon Phone: +351 919994372 Fax: +351 211808178E-mail: rita.ferreira@inodia.pt Web: www.inodia.pt

RomaniaCanori imex SRL9-15 Maior Coravu Str. Bl. C5, Sc. B, Ap. 51, Sector 2 BucharestPhone: +40 21 250 19 29Fax: +40 21 250 19 06E-mail: office@canori.roWeb: www.canori.ro

Distributors

Diagnostics

SingaporevCell Science Pte Ltd. 41 Science Park Road, The Gemini Singapore Science Park II, Singapore 117610 Phone: +65 6778 8166Fax: +65 6778 8132 E-mail: info@vcellscience.com Web: www.vcellscience.com

SlovakiaLAB MARK a.s.Pod Cihelnou 23161 00 Praha 6Phone: +420 233 335 548Fax: +420 233 335 930E-mail: labmark@labmark.czWeb: www.labmark.cz

South AfricaBiocom Biotech P.O. Box 13004 0014 Clubview Phone: +27 12 654 4614 Fax: +27 86 654 9048 E-mail: info@biocombiotech.co.zaWeb: www.biocombiotech.co.za

SpainLabClinics S.A.C. Industria, 54E-08025 BarcelonaPhone: +34 93 446 47 00Fax: +34 93 348 10 39E-mail: info@labclinics.comWeb: www.labclinics.com

Sri LankaCPC Diagnostics Pvt. Ltd. No.9, 5th floor, Gokul Tower 9&10 C.P. Ramaswamy Road Alwarpet, Chennai - 600 018 Phone: +91 44 24993989 Fax: +91 44 24993357 E-mail: immuno@cpcdiagnostics.in Web: www.cpcdiagnostics.in

SwitzerlandLucerna Chem AG Abendweg 18CH-6006 Luzern Phone: +41 41 420 96 36 Fax: +41 41 420 96 56 E-mail: lucerna-chem@lucerna-chem.chWeb: www.lucerna-chem.ch

TaiwanBlossom Biotechnologies Inc.2F-6, No.32, Sec. 1, Cheng-gung Rd.Nangang 11570, TaipeiPhone: +886 2 2788 2121Fax: +886 2 2782 9911E-mail: blossom@blossombio.com.twWeb: www.blossombio.com.tw

TurkeyMedSanTek Ltd. Co.Millet Cad. Findikzade Sok.Emre Apt. No:19/5 34093, Findikzade-IstanbulPhone: +90 212 635 85 46Fax: +90 212 635 83 50E-mail: info@medsantek.com.trWeb: www.medsantek.com

United KingdomCaltag-Medsystems Ltd Botyl Road, Botolph Claydon MK18 2LR Buckingham Free call: 800 279 9113 Phone: +44 (0)1296 715459 Fax: +44 (0)1296 715718 E-mail: sales@caltagmedsystems.co.ukWeb: www.caltagmedsystems.co.uk

USAABR Affinity BioReagents (Thermo Fisher Scientific)4620 Technology DriveSuite 600, Golden, CO 80403Free call: 800 527 4535Phone: +1 303 278 4535 Fax: +1 303 278 2424E-mail: affinity@bioreagents.comWeb: www.bioreagents.com

Assay Designs, Inc5777 Hines Drive Ann Arbor, MI 48108 Free call: 800 833 8651 Phone: +1 734 668 6113 Fax: +1 734 668 2793 E-mail: info@assaydesigns.comWeb: www.assaydesigns.com

Cedarlane Laboratories U.S.A.1210 Turrentine StreetBurlington, NC 27215Free call: 800 721 1644Phone: +1 336 513 5135Fax: +1 336 513 5138E-mail: service@cedarlanelabs.comWeb: www.cedarlanelabs.com/us

Quidel CorporationSpecialty Products Group2981 Copper Road, Santa Clara, CA 95051Free call: 800 524 6318Phone: +1 408 616 4301Fax: +1 408 616 4310E-mail: custsvc.spg@quidel.com Web: www.quidel.com

Distributors

Diagnostics

Distributed by:

BioPorto Diagnostics A/SGrusbakken 8DK-2820 GentofteDenmark

Phone (+45) 4529 0000Fax (+45) 4529 0001E-mail info@bioporto.comWeb www.bioporto.com

Diagnostics

product catalogue

acute renal failure

acute kidney injury

ngal levels rise

neutrophil gelatinaseassociated lipocalin

early urinary biomarker

elisa kits

renal function

kidney injury

Documents

product catalogue 2020 - prominent › resources ›...

product catalogue - medicare...product catalogue. product...

product catalogue - morley-ias.be · product catalogue...

product catalogue catalogue de produits

product catalogue product catalogue

product catalogue - pentagon product catalogue... ·...

sapne product catalogue oct'17 for web -...

product catalogue -...

product catalogue-pdf - silverback cargo · pdf fileproduct...

product catalogue

product catalogue - namibia quality beverages · nqb...

product catalogue - reus · product catalogue 201.01...

product catalogue nuts & washers - fortress -...

ibs technics · web viewibs product catalogue ibs product...

product catalogue - product catalogue - edition...

yealink product catalogue yealinnkk product catalogue...

product catalogue socket screws - fortress...

product catalogue 2021 product catalogue volume 1